Journal Logo

News

Genomic Analysis of Diffuse Large B-Cell Lymphoma

doi: 10.1097/01.COT.0000534131.10647.4f
  • Free

The majority of patients with diffuse large B-cell lymphoma (DLBCL) can be treated effectively. However, people whose disease recurs face a shortage of good options, especially because the disease is driven by a complicated mix of genetic alterations. Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease's many forms, which will help to predict individual patient outcomes and guide personalized treatment (Nat Med 2018; doi:10.1038/s41591-018-0016-8).

Analyzing 304 patient samples, the study showed that DLBCL tumors can be divided into five genetic subtypes, noted Margaret Shipp, MD, Chief of Dana-Farber's Hematologic Neoplasia division and Director of the Lymphoma Program of the Dana-Farber/Harvard Cancer Center.

“These genetic signatures also clearly suggest that we want to think about using a combination of targeted agents, because in DLBCL, combinations of genetic alterations occur together in specific subtypes,” she explained.

About 60 percent of patients can be treated successfully with a combination of four chemotherapies plus a targeted drug that inhibits a B-cell surface protein. “But the other very substantial fraction of patients develops recurrent disease, and their treatment options are far less successful,” stated Shipp.

Current clinical tests do a relatively good job of predicting which patients with DLBCL can be treated effectively with standard treatments, but the tests do not offer insights into how treatments could be improved for other patients. The Dana-Farber/Broad collaboration is among several research groups bringing genomic tools to this task. An earlier effort led by NCI scientists established a widely used “cell of origin” classification scheme for DLBCL, which employed RNA profiling to categorize tumor cells by stages of normal B-cell development.

Unlike previous DLBCL research efforts, Shipp noted the Dana-Farber/Broad collaboration sought to integrate data on three types of genetic alterations that can drive tumors-mutations to genes, changes in gene copy numbers and chromosomal rearrangements-and define previously unappreciated disease substructure.

“Specific genes that were perturbed by mutations could also be altered by changes in gene copy numbers or by chromosomal rearrangements, underscoring the importance of evaluating all three types of genetic alterations,” Shipp explained. “Most importantly, we saw that there were five discrete types of DLBCL that were distinguished one from another on the basis of the specific types of genetic alterations that occurred in combination.”

The investigators followed up to examine these tumor subtypes by RNA data associated with cell of origin. They found that each of the two major cell-of-origin subtypes could be split into separate categories with distinct genetic signatures. An additional subtype defined by TP53 gene alterations and associated genomic instability was unrelated to cell of origin. The team then went on to discover clear links between given genetic subtypes and how patients responded to standard treatment.

The study underlined the high genetic diversity in DLBCL—for instance, the median number of genetic driver alterations in individual tumors was 17. “That large number of alterations tells us that we need to understand the complexity of the genetic signature, because it's unlikely that simply focusing on one genetic alteration will be enough to target therapeutically,” Shipp pointed out. “By understanding the genetic basis of that heterogeneity, we will be able to apply more specifically targeted agents that have the highest likelihood of impacting the right pathways in the right patients.”

Wolters Kluwer Health, Inc. All rights reserved.
    Home  Clinical Resource Center
    Current Issue       Search OT
    Archives Get OT Enews
    Blogs Email us!